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Because the stress protein GRP94 can augment pres-
entation of peptides to T cells, it is important to define
how it, as well as all other HSP90 family members, binds
peptides. Having previously shown that the N-terminal
half of GRP94 can account for the peptide binding ac-
tivity of the full-length protein, we now locate this bind-
ing site by testing predictions of a molecular docking
model. The best predicted site was on the opposite face
of the  sheet from the pan-HSP90 radicicol-binding
pocket, in close proximity to a deep hydrophobic pocket.
The peptide and radicicol-binding sites are distinct, as
shown by the ability of a radicicol-refractive mutant to
bind peptide. When the fluorophore acrylodan is at-
tached to Cys117 within the hydrophobic pocket, its flu-
orescence is reduced upon peptide binding, consistent
with proximity of the two ligands. Substitution of His125,
which contacts the bound peptide, compromises pep-
tide-binding activity. We conclude that peptide binds to
the concave face of the  sheet of the N-terminal domain,
where binding is regulated during the action cycle of
the chaperone.
Glucose-regulated protein 94 (GRP94),1 also known as gp96,
is a member of the HSP90 family of molecular chaperones and
can dramatically stimulate T cell responses by two mecha-
nisms: enhancement of peptide presentation to the adaptive
arm of the immune system (1) and stimulation of innate im-
munity (2). Because of these activities, tumor-derived GRP94
can be used to elicit immune response against the tumor and is
potentially a powerful immunotherapeutic tool (3). The anti-
gen-presentation activity was shown not to be due to any mu-
tation in GRP94 that would enhance its immunogenicity, but
rather due to its ability to bind peptides (1, 4). The GRP94-
peptide complexes are known to be taken up by a subset of
antigen-presenting cells via receptor-mediated endocytosis (5),
and the chaperoned peptides are then re-presented on endog-
enous antigen-presenting cells MHC class I molecules on the
cell surface. Although peptide binding is a general activity of
many molecular chaperones, it has been argued that GRP94 is
among the most effective of such chaperones in enhancing
antigen presentation.
Despite its importance, the GRP94-peptide interaction and
the identity of the peptide-binding site have not been charac-
terized in detail. They are crucial issues toward understanding
the immunostimulatory action of GRP94. The mode of peptide
binding by GRP94 may also inform about its activity as a
chaperone of selected membrane-bound and secreted proteins
(6), although the connection between the two activities is yet to
be elucidated. The same questions are also unanswered for all
other HSP90 chaperones, despite the central role of these cy-
tosolic chaperones in organizing signaling complexes and reg-
ulating transcription factor (6). Several peptides derived from
vesicular stomatitis virus (VSV) have been shown to bind
GRP94. VSV8 is an octamer (RGYVYQGL) from the N protein
of VSV and is the dominant T cell epitope of the virus, pre-
sented via MHC class I Kb to specific T cells (7). The structure
of a complex of this peptide with MHC class I has been solved
(8). VSV8 has been eluted from GRP94 purified from a VSV N
protein-transfected cell line (9), and the peptide has been
shown to bind directly to purified GRP94 in vitro (1). Peptide A
is a 15-mer (KRQIYTDLEMNRLGK) from the glycoprotein of
the virus and is not known to be immunogenic (1, 10, 11).
However, this peptide binds GRP94, as do other peptides from
the VSV G protein, including LSSLFRPKRRPIYKS (1). An-
other viral peptide known to bind GRP94 is YVNTNMG from
the core protein of hepatitis B virus, which is similar to a
known HLA-A11 antigenic peptide (12). The only non-viral
peptides rigorously shown to bind GRP94 are the ovalbumin
257SIINFEKL264 peptide (13), and a mouse leukemia tumor
antigen IPGLPLSL from a mutated Akt (14).
No common sequence motif is obvious from comparing these
peptides. Spee and Neefjes (15) used radioactive peptides with
photo-reactive side chains to explore the peptide preferences of
GRP94. No obvious size preference was found, and even 40-
mers could bind the chaperone. The only sequence specificity
found was that 9-mers with basic or acidic amino acids in
positions 2 and 9 bind relatively weakly to GRP94. In two
cases, the VSV N-derived and the RBL tumor-derived antigens
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(1, 14) not only are the octamer antigenic peptide associated
with GRP94, but also their larger precursors. This raises the
question of what sequence or structure features are compatible
with peptide binding to GRP94.
The limited amount of information about the peptide binding
activity of GRP94 is due in part to the low stoichiometry of
binding (only about 1% of the protein had been shown to bind
peptides (16)) and slow binding kinetics (17). These technical
obstacles also hindered the identification of structural deter-
minants of the peptide-binding site and its regulation. We
showed that the N-terminal third of GRP94 constituted a pep-
tide-binding entity and demonstrated that peptide binding to
this fragment is specific, is inhibited by the pan-HSP90 inhib-
itors radicicol and geldanamycin, and has a binding stoichiom-
etry close to 1 mole of peptide per mole of GRP94 (17). In
addition, our data indicated that the peptide specificity of this
site is different from that of another endoplasmic reticulum-
resident stress protein, BiP (17). In the present work we use
molecular modeling, biochemical characterization, and site-di-
rected mutagenesis to identify a peptide-binding site located
within the N-terminal domain, on the face opposite the radici-
col-binding site, and show that His125 is located in the binding
site and is directly involved in the binding activity.
EXPERIMENTAL PROCEDURES
Recombinant Proteins
N1–355—The construct for expression of N1–355 in insect cells and
the purification procedure are described previously (17). Recombinant
N1–355 contained an N-terminal His6 tag, followed by the first 355
amino acids of a mature sequence of GRP94 and a C-terminal ER1
targeting signal KDEL.
N34–355—The sequence coding for the first 33 amino acids of N1–
355 was deleted by PCR cloning. The resultant PCR product was in-
serted into the pQEXa vector (Qiagen) using BamH1 and XmaI so as to
add a His6 tag followed by a factor Xa recognition sequence at N
terminus. The plasmid was transformed into M15 Escherichia coli,
which were allowed to grow to mid-log phase and then incubated with
1 mM isopropyl-1-thio--D-galactopyranoside for 4 h at 27 °C to induce
protein expression. Bacteria were harvested and lysed in 1% Nonidet
P-40 (Sigma Chemicals) in 20 mM phosphate buffer, pH 7.2, containing
500 mM NaCl and 20 mM imidazole. N34–355 was purified from the
detergent lysates by affinity chromatography on Ni-NTA columns (Qia-
gen), according to the manufacturer’s instructions. Bound proteins were
eluted with 500 mM imidazole, dialyzed, and concentrated. The protein
was stored in 25 mM HEPES (pH 7.2), 110 mM KOAc, 20 mM NaCl, 1 mM
Mg(OAc)2, 0.1 mM CaCl2 (buffer A) containing 10–20% sucrose at
80 °C. When needed, the N-terminal extension containing the His6
tag was removed by digestion with factor Xa (Novagen) according to the
manufacturer’s instructions. The reaction mixture was re-purified over
a Ni-NTA column, and the flowthrough containing only the cleaved
N34–355 was used. The cleaved protein appeared 2–3 kDa smaller on
SDS-PAGE compared with the parent protein, consistent with the
removal of 17 amino acids (not shown). After digestion, the heptamer
PYNGTGS precedes Ala34 of the mature N34–355 sequence.
Mutant Proteins—Amino acids substitutions were introduced into
the vector encoding N34–355 with the QuikChange kit (Stratagene).
Mutations were verified by sequencing and, when appropriate, by re-
striction enzyme analyses. The proteins were expressed in bacteria and
purified as described above.
Peptides
Peptides were synthesized at the University of Chicago facility and
verified by mass spectroscopy. The sequences of the two binder peptides
were: VSV8, RGYVYQGL, from the VSV N protein; Pep A, KRQIYT-
DLEMNRLGK, from the VSV G protein. Stock solutions were prepared
in water and stored at80 °C. Peptide concentrations were determined
by a BCA assay (Pierce). Where indicated, peptides were iodinated by
the IODO-BEADs method (Pierce), and unincorporated iodine was re-
moved by passage over a short Dowex AG 1-X8 column. The specific
radioactivity of the peptides was routinely 2 1014 to 1 1015 cpm/mol.
Peptide Binding Assays
Two types of binding assays were used. The solution binding assay
was performed as described previously (17). Briefly, recombinant pro-
teins were incubated with iodinated peptide under saturating condi-
tions, and radioactivity associated with protein-peptide complexes was
measured after separation of free peptide over spin columns containing
0.2–0.8 ml of packed P-30 beads (Bio-Rad) in buffer A. Iodinated pep-
tide without protein was used as background control for spin column
separation.
A solid-phase binding assay (referred to as plate assay in the text) is
described and validated elsewhere.2 Briefly, 96-well plates (Costar 3590
High Binding, Corning, NY) were coated with peptides prior to assay,
and the recombinant proteins in 100 l of buffer A were allowed to bind
for 90 min. Binding was quantified by HRP-rabbit anti-His6 (Amersham
Pharmacia Biotech), and color development was monitored at 415 nm
with a BioTek plate reader. Because both N1–355 and N34–355 nor-
mally reached saturation at the input level of 0.7 or 1 g, the A415 value
at this level was defined as 1, and all data points were normalized to it.
Inhibition by 300 M radicicol (Sigma; stock solution in Me2SO) was
used as a specificity control.
Because peptide binding to GRP94 is saturable and specific, yet the
off-rate is exceedingly slow (17), Ka values were estimated graphically
from the fractional occupancy curves (A415 value at a given protein
input relative to A415 value at saturation as a function of protein input).
When the binding reaction is not in equilibrium, these values are valid
as comparative parameters among the various mutants.
Gel Electrophoresis
Analysis of protein conformation by blue native gel electrophoresis
was accomplished by using 5–15% gradient acrylamide gels in the
Laemmli gel system without SDS (18), with Coomassie Brilliant Blue
G-250 (Sigma Chemicals) included in the cathode buffer. Thyroglobulin,
ferritin, and bovine serum albumin were used as molecular weight
standards.
Protein Modifications
Binding of the fluorescent dye 8-ANS (Molecular Probes, Eugene,
OR) to proteins was performed by incubating 5 M ANS with 0.5 M of
the appropriate N355 construct in 500 l of buffer A.
For acrylodan (6-acryloyl-2-dimethylaminonaphthalene) modifica-
tion, recombinant protein (10 M) was incubated at 4 °C overnight in
the presence of 100 M acrylodan (Molecular Probes) in 50 mM ammo-
nium acetate buffer, pH 6.9, and free acrylodan was removed using a
spin column. For the experiments measuring the effect of peptide on
N355-acrylodan, peptide was added to the final concentration of 100 M;
equivalent volume of buffer was added to control samples. The mixtures
were heat-shocked at 50 °C for 10 min and diluted to 500 l, and
fluorescence measurements were performed on a PTI fluorometer. Sam-
ples were excited at 350 nm for ANS and 390 nm for acrylodan, and the
emission spectra were collected between 400 and 600 nm. The slit
widths were set at 2 nm for excitation and 2–6 nm for emission.
Before modification of histidines with DEPC, wild type, or H125D
N34–355 (800 g each) were treated with 24 units of factor Xa (Nova-
gen) in buffer A overnight at 25 °C and then repurified using Xarex-
agarose (Novagen) to remove factor Xa and Ni-NTA-agarose to remove
the His6-containing peptide. The His-cleaved proteins were reacted
with peptide A (or solvent alone) at 12 M protein and 2.8 mM peptide
in buffer A overnight at 25 °C. Free peptide was removed, and the
buffer was exchanged to 50 mM ammonium acetate, pH 6.8, using P10
spin columns. Both free N34–355 and the protein-peptide complexes
were reacted with 1 mM DEPC (Sigma Chemical Co.) at 25 °C or with
EtOH as a solvent control. Incubation for 15–20 min gave complete His
modification, as determined by monitoring the reaction at 240 nm (19).
Where indicated, the carbethoxyhistidine was reverted back to histi-
dine by treatment with 400 mM hydroxylamine for 15 min at 25 °C (20).
Mass Spectrometry
Samples were diluted to 20 M final concentration in sinapinic acid
saturated with acetonitrile and 1% trifluoroacetic acid. 1–2 l of each
sample was adsorbed onto a Ciphergen gold chip and allowed to air dry.
Masses were measured by using the surface-enhanced laser desorption
ionization/time-of-flight ProteinChip Reader (Ciphergen).
RESULTS
GRP94-bound Peptide Is Contained within a 188-Residue
Fragment—Previously we demonstrated that a truncated ver-
sion of GRP94, containing amino acids 1–355, is sufficient to
2 C. Biswas, T. Gidalevilz, and Y. Argon, manuscript in preparation.
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account for the ability of the full-length protein to bind immu-
nologically relevant peptides, such as the VSV major T cell
antigen, VSV8. We also showed that this activity was subject to
regulation by the pan-HSP90 inhibitors radicicol and geldana-
mycin (17). To further locate this peptide-binding site, a shorter
version of recombinant GRP94 that lacked the first 33 amino
acids of the mature protein (N34–355, Fig. 1A) was cloned and
over expressed in E. coli. This recombinant protein bound
VSV8 with a binding curve very similar to that of N1–355 (Fig.
1B), showing that the first 33 amino acids are not essential for
the peptide-binding activity. To define an even smaller frag-
ment containing the peptide-binding site, we took advantage of
the single thrombin site in N34–355, C-terminal to Arg222, and
asked whether a complex of N34–355 and peptide remains
intact after cleavage with thrombin. Following the digestion,
two bands were detectable by Coomassie Blue staining corre-
sponding to the predicted N-terminal 22.4-kDa and C-terminal
14.6-kDa fragments (Fig. 1C). The assignment of the fragments
was confirmed by antibodies specific to either the N terminus of
N34–355 (anti-His6) or to residues 261–276 near the C termi-
nus (9G10 (21)). Because the GRP94-peptide complex is resist-
ant to SDS (1, 17) peptide-bound protein fragments can be
detected after SDS-PAGE by the radioactivity of the bound
iodinated peptide. In the absence of thrombin, a radioactive
band corresponding to the uncleaved complex was detectable.
After partial thrombin digestion, an additional radiolabeled
band of apparent molecular mass of 22.4 kDa was detected
after SDS-PAGE separation, whereas the other 14.6-kDa frag-
ment was not labeled (Fig. 1C). These data suggest, therefore,
that amino acids 34–222 of GRP94 are sufficient to retain the
bound peptide.
Molecular Modeling of the GRP94-Peptide Complex—We
next took advantage of previously published data (22, 23) to
create a computer model of potential peptide-binding sites.
First, we used the crystal structure of the N-terminal domain of
HSP90 (Protein Data Bank files 1YER and 1A4H) to generate
an energy minimized, predicted structure of the highly homol-
ogous segment of GRP94 (51% identity between yeast HSP82
and mouse GRP94). Second, we used the known structure of
the antigenic peptide VSV8, which was determined in associa-
tion with MHC class I (2MHC (8)). Third, making the simpli-
fying assumption that the conformation of VSV8, when bound
to GRP94, is essentially similar to its conformation when
bound to MHC class I, we used the docking algorithm Patch-
Dock (24) to predict potential binding sites. The algorithm
searches the protein surface for locations with highest geomet-
ric shape complementarity to the ligand molecule and docks the
ligand into these locations. Such docking solutions usually
produce clusters in different protein cavities, because binding
in cavities enables greater shape complementarity. In addition,
statistical data about atomic contacts of VSV8 with MHC class
I was collected and used to score the docking solutions. The
highest scoring solutions in terms of shape complementarity
and statistical score were selected.
The Peptide-binding Site Is Distinct from the Radicicol-bind-
ing Pocket—The seven best solutions mapped to two potential
docking sites. One site overlaps with the radicicol-binding
pocket (Fig 2A), the largest cavity in the protein. This site was
considered unlikely, because previous data showed that radi-
cicol and peptide could bind simultaneously. We therefore
asked whether mutants that did not bind radicicol could still
bind peptides. Relying on the solved structure of the complex
between yeast HSP90 N-terminal domain and radicicol (23)
and on the similarity between HSP90 and GRP94 (25), we
mutated residues Asp128 and Gly132 simultaneously, to Asn
and Ala, respectively. Asp93 in HSP90 (corresponding to Asp128
in GRP94) makes a crucial hydrogen bond with radicicol, and
Gly97 packs tightly against the inhibitor and also serves to
position helix 4, an important portion of the binding pocket (22,
23, 26). The D93N mutant of HSP90 does not bind ATP (27), so
the double mutant of GRP94 was expected to be unable to bind
radicicol. Recombinant N34–355 D128N,G132A mutant (RadR)
was soluble, mostly monomeric, and expressed the conforma-
tion-sensitive epitope for the antibody 9G10, like the wild type
protein. To test whether the RadR mutant binds radicicol, we
used two functional tests (see Ref. 17 for details): loss of the
9G10 epitope and acquisition of a compact conformation with
increased mobility in native blue gels. Both changes have been
shown to reflect the conformational change in the protein upon
radicicol binding (17). The resultant mutant was refractive to
treatment with radicicol, as judged by the continued exposure
of the 9G10 epitope (data not shown) and lack of acquisition of
a compact conformation (Fig. 3A). Despite lack of radicicol
binding, the RadR protein bound peptide effectively (Fig. 3C),
with only a small reduction in the apparent association con-
FIG. 1. A minimal portion of GRP94 is sufficient for peptide
binding. A, schematic of recombinant proteins used. N1–355, the pro-
tein used in (17), contains the first 355 amino acids of GRP94, starting
from the DDEVD N terminus of the mature protein. N34–355 is a
version expressed in bacteria, where the first 33 amino acids of mature
GRP94 are deleted. Hatched box, the N-terminal domain, containing
the nucleotide/geldanamycin/radicicol-binding site. Dark gray box, an
acidic domain needed for at least one of the activities residing in the
N-terminal domain. Light gray box, His6 tag. In N34–355 the tag is
followed by a factor Xa cleavage site. N1–355 terminates with a KDEL
endoplasmic reticulum retrieval signal, which is absent in N34–355.
The single thrombin cleavage site after Arg222 is marked, as is the
region containing the 9G10 monoclonal anti-GRP94 epitope (*). B, pep-
tide binding ability of N1–355 and N34–355. The two versions of re-
combinant chaperone were tested, at the doses indicated, for binding of
the 8-mer peptide VSV8 in the 96-well plate assay (see “Experimental
Procedures”). Filled triangles, N1–355; filled squares, N34–355; empty
symbols show inhibition of peptide binding by radicicol. C, thrombin
digestion of N1–355-iodinated peptide complex. C.B., Coomassie Blue-
stained gel after partial proteolysis with thrombin, showing the cleav-
age of the recombinant protein into two fragments. 125I, autoradiogra-
phy of the same gel, showing that the iodinated peptide co-migrates
with the larger thrombin fragment. -His, Western blot for the N-
terminal His tag identifying the 22.4-kDa band as the N-terminal
fragment. 9G10, Western blot for the epitope residing in the acidic
domain identifying the 14.6-kDa band as the C-terminal fragment. The
larger band at the top of the gels is undigested material.
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stant compared with the WT protein. Consistent with the lack
of radicicol binding, the peptide-binding activity of RadR mu-
tant was not inhibited by pre-treatment with radicicol, whereas
the activity of wild type N34–355 was inhibited significantly
(Fig. 3B). We conclude that not only is the peptide-binding site
within N34–355 distinct from the radicicol-binding site (17),
but abolition of inhibitor binding does not affect the ability to
bind peptides.
Peptide Binding Affects the Environment of the Binding Site
for Two Hydrophobic Probes—The other potential peptide
docking site is on the opposite side of the  sheet, where there
is a large saddle-like surface made of eight  strands. Side
barriers to this saddle are provided by two loops, Asp170-Arg222
and Lys119-Asn122, plus part of a strand H (Val260-Ser263) that
is the end of the modeled sequence (Fig. 2B). Four of the
highest scoring solutions predicted that VSV8 could fit well
within this saddle (Fig. 2B). The peptides would fit at an angle
of 70° relative to the long axis of the  sheet across strands
E–H, and most of the surface contact would be with the  sheet.
This putative peptide-binding site is in close proximity to a
deep hydrophobic pocket (Fig. 4). Hydrophobic residues from
strands E, F, G, and H, as well as from the helix and loop leading
to the strand H and the long helix are predicted to form this
pocket. The edge strand (H) of the  sheet and preceding loop,
which form a part of an entrance to this pocket (Fig. 4B), have
been shown to contribute to the binding site of the hydrophobic
dye bis-ANS (28). We therefore speculated that this pocket can
accommodate various hydrophobic probes, such as bis-ANS,
ANS, acrylodan, and Nile Red, which have been reported to bind
to GRP94 (11, 28) (detailed characterization of this hydrophobic
pocket is provided elsewhere). The emission spectrum of ANS-
labeled N1–355 had a maximum around 474 nm (Fig. 5A), as
expected if ANS was indeed bound in a hydrophobic environment
(29). When ANS-labeled N1–355 was incubated with peptide A,
the intensity of ANS fluorescence decreased and its emission
maximum was blue-shifted slightly (Fig. 5A). Such decreased
ANS fluorescence is consistent with peptide A binding affecting,
either directly, or via conformational changes, the environment
of the fluorophore. Alternatively, if ANS and peptide compete for
the same binding site, it may be due to the release of ANS. The
latter explanation can be ruled out due to blue shift of ANS
emission, so we favor the notion that peptide binds in proximity
to the hydrophobic pocket.
If peptide in fact binds as predicted, it should also affect the
environment of other hydrophobic probes. Strand G has the
sole cysteine residue (Cys117) in N1–355, whose side-chain
points into the hydrophobic pocket (Fig. 4), so we modified the
protein with the Cys-specific naphthalene derivative acrylodan
(11, 30). Although acrylodan has a very low quantum yield in
aqueous solutions, its fluorescence is markedly increased upon
reaction with thiols (30), and then the fluorescence is highly
sensitive to the hydrophobicity of its environment. As shown in
Fig. 5B, when excited at 390 nm, acrylodan-modified N1–355
had emission maximum around 474 nm, as expected if the
fluorophore was in a highly hydrophobic environment. Free
acrylodan had a maximum at about 520 nm. Denaturation of
the N1–355-acrylodan conjugate with 6 M guanidine hydrochlo-
ride abolished the fluorescence at 474 nm and gave rise to the
FIG. 2. Molecular docking model. The relevant sequence of murine GRP94 (from amino acid 46 to 269) was threaded through the solved
structure of the N-terminal domain of yeast HSP90 (PDB file 1YER (26)), using the BioSym software, and energy minimized. The structure of the
peptide VSV8 was taken from the solved structure of the complex of VSV8 and MHC class I Kb (8). VSV8 was then docked onto the modeled GRP94
structure using the program PatchDock, assuming that it would bind to GRP94 in the same conformation as to MHC class I. The highest ranking
docking solutions are shown. They are divided between two possible sites, shown in green in panels A and B, respectively. A, three peptide docking
solutions partially overlap with the radicicol/geldanamycin-binding site. Left panel, side view from the C-terminal end along the axis of the  sheet.
Right panel, bottom view. White oval, outline of the radicicol-binding site. B, four docking solutions map over part of the  sheet. Left panel, view
along the axis of the  sheet, same as in A. Right panel, top view. The sole cysteine and three histidines are shown in ball-and-stick representation,
in yellow and light blue, respectively. Red arrow, Cys117; red arrowhead, His125; A–H, strands of the  sheet.
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same emission maximum as free acrylodan in 6 M guanidine,
indicating that the observed fluorescence is dependent on the
tertiary structure of the protein. As expected for the covalent
modification, the fluorescence intensity of the denatured N1–
355-acrylodan conjugate was significantly higher than that of
free acrylodan (Fig. 5B). These spectral properties fulfill the
expectation that acrylodan is located in a hydrophobic pocket
when bound covalently to Cys117. Therefore, acrylodan modifi-
cation of N1–355 provides a defined fluorescence probe for
detection of molecular changes.
To test whether modification with acrylodan affects peptide
binding by N1–355, we incubated acrylodan-modified and un-
modified proteins with a saturating amount of iodinated VSV8
and measured peptide binding to each. Acrylodan-conjugated
protein was capable of binding peptide essentially like the
unmodified protein (Fig. 5C), showing that acrylodan does not
interfere with the binding activity. Importantly, the fluores-
cence of acrylodan was partly quenched in the presence of
peptide (Fig. 5D). These data are in good agreement with the
model in Fig. 2B, which predicts that the peptide-binding site is
distinct from but in close proximity to the hydrophobic pocket.
These data cannot, however, distinguish quenching due to
peptide binding in close proximity to the acrylodan from that
due to conformational changes as a result of peptide binding to
a more distant site. However, we have shown previously (17)
that peptide binding does not induce the same conformational
change as inhibitor binding, nor does it alter protease sensitiv-
ity of N355 (data not shown), arguing against global conforma-
tional changes. This, together with the data presented below
(Table I), argue in favor of peptide binding in proximity to
Cys117.
Peptide Binding Is Sensitive to Modification of Histidine
Residues—The third approach to defining the peptide-binding
site derived from the observation that peptide binding was
pH-sensitive (Fig. 6A and Ref. 17). Binding was inhibited above
pH 7.2 and was stimulated at pH near 6.0. In addition, binding
was sensitive to imidazole; the presence of 6 mM imidazole
reduced peptide binding by half (Fig. 6B). Both observations
suggested that histidine residues might be involved in peptide
binding by GRP94. Diethyl pyrocarbonate (DEPC) N-carbe-
thoxylates the imidazole ring of histidine in a highly specific
manner under certain conditions (19, 20) and is therefore use-
ful in defining the role of histidines. DEPC treatment of N34–
355 (after cleavage of the His6 tag) abolished the peptide-
binding activity of the protein as effectively as the inhibitor
radicicol, whereas the ethanol solvent alone had no inhibitory
effect (Fig. 6C). Hydroxylamine (HA) treatment restored the
activity of the DEPC-modified protein (Fig. 6C), confirming
that only modified His residues and not other amino acids (20)
were important for the change in activity.
His125 Is Important for Peptide Binding—The N34–355 pro-
tein has four His residues, at positions 125, 194, 200, and 353.
Based on the model (Fig. 2B), His125 was deemed to be the
histidine residue most likely to be involved in the peptide-
binding site. We therefore mutated His125 to either Asp, alter-
ing the charge, or to Tyr, replacing the imidazole ring with a
phenol ring. The mutated H125D protein had almost no pep-
tide binding activity, and the H125Y protein - only partial
activity (Fig. 7A). Because the binding reaction has an unusu-
ally slow off-rate (17) and therefore is not in equilibrium, Hill
plots cannot be used to calculate the affinity, but the fractional
occupancy plot can be used to estimate the association con-
stants. The fractional occupancies calculated for the wild type
and H125Y proteins are superimposable (Fig. 7B), showing no
significant difference between the association constants of the
wild type and H125Y proteins. Because the saturation level of
H125Y is 0.6 of that of wild type, this analysis suggests that
the H125Y mutation affects the active fraction of the protein,
rather than binding by the active fraction.
The loss of binding activity is not due to global misfolding of
the mutant proteins. First, both were purified as soluble pro-
teins and displayed chromatographic properties akin to the
wild type protein. Second, both H125D and H125Y expressed
the monoclonal 9G10 epitope (data not shown). Third, H125D
retained its ability to bind the inhibitor radicicol and respond to
it by altering its conformation, as shown by the native gel
mobility test in Fig. 7C. The same test shows that approxi-
mately half of the H125Y mutant is found in the fast migrating
conformation even in the absence of radicicol, supporting the
conclusion that the H125Y mutation decreases the fraction of
active protein. However, the population of this protein that
shows correct mobility (50%) does appear to be capable of
radicicol binding-induced conformational change (Fig. 7C). The
relative abundance of this population is in agreement with the
peptide saturation level of H125Y (0.6 of that of wild type,
Fig. 7A). Therefore, tyrosine at position 125 of N34–355, al-
though decreasing the proportion of active protein, does not
preclude peptide binding per se. Because, in contrast to histi-
dine and tyrosine, aspartic acid at position 125 abolishes pep-
tide binding, we propose that the nature of residue 125 is
critical for peptide binding, confirming a strong prediction of
the structural model.
His125 Is in Physical Proximity to the Bound Peptide—Al-
FIG. 3. The radicicol-refractive mutant N34–355 D128N,G132A
still binds peptide. A, D128N, G132A mutant of N34–355 (RadR) is
refractive to radicicol treatment. N34–355 (WT) and RadR proteins
were incubated for 15 min with either Me2SO or radicicol and resolved
on a blue native gel. Radicicol-bound WT protein migrates through the
gel more rapidly, due to a conformational change in the protein (17).
The ability of the RadR protein to bind radicicol is dramatically re-
duced. Black arrow, unmodified protein; white arrow, radicicol-bound
protein. B, peptide binding by RadR mutant is not affected by radicicol
and is similar at saturation to that of WT protein. Binding of N34–355
and RadR proteins to VSV8 peptide was measured by the plate assay
(see “Experimental Procedures”). Black bars, binding in the absence of
inhibitor; gray bars, binding in the presence of radicicol. Data are
averages of triplicate samples. C, dose binding of N34–355 and RadR
proteins. Binding to VSV8 peptide was measured in a plate assay.
Circles, WT protein; squares, RadR mutant. Data are averages of trip-
licate samples.
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though the data above show that the environment of Cys117
changes upon peptide binding and that His125 modification
either by DEPC or by a charge-altering mutation abolishes
peptide binding, they can be explained in terms of transmission
of conformational changes and thus do not formally show phys-
ical association. Therefore, we used the DEPC modification
procedure in a peptide-protection experiment. The extent of
DEPC modification was compared between a peptide-bound
and peptide-free N34–355 (from which the His6 tag was re-
moved), reasoning that, if peptide is bound as modeled, it
should protect His125 from modification. The proteins were
analyzed by surface-enhanced laser desorption ionization/time-
of-flight mass spectrometry (Table I). Each N-carbetoxylation
adds 72 Da per His residue modified. The mass of N34–355
modified with DEPC increased by 289 Da compared with the
unmodified protein, as expected from modification of all four
His residues. That only His were modified was shown by the
reversibility of the mass increase upon subsequent treatment
with hydroxylamine (20). When N34–355 was saturated with
peptide A prior to the modification with DEPC, the mass gain
was 73 Da less than in the absence of peptide (Table I), as
expected if one residue was protected from DEPC modification.
Mass spectrometry of proteolytic fragments of DEPC-modified
proteins confirms that the protected residue is His125 (data not
shown). When the H125D mutant was used in the same man-
ner, its mass increased by only 211–215 Da after modification
with DEPC, whether peptide was present or not, as expected
from a protein with only 3 His and unable to bind peptide
(Table I). These modification experiments argue that of the four
histidines, only His125 is involved in peptide binding, and it is
physically associated with the peptide.
DISCUSSION
Many molecular chaperones recognize their substrates by
binding to peptide sequences. Deciphering how GRP94 binds
peptides is important not only for understanding how it acts as
a chaperone, but also for understanding how it is able to stim-
ulate peptide-specific T cell responses. The work presented
FIG. 4. The predicted peptide-binding site is in proximity to a deep hydrophobic pocket and to the inhibitor-binding site. A,
multiple sequence alignment of parts of the N-terminal domains of GRP94 and HSP90. Black lines above the sequence, strands G and F (see B),
containing Cys117 and His125, respectively. Red lines below the sequence, inhibitor-binding pocket constituents (22, 26) within the partial sequence.
Green line, 35 amino acids in HSP90 whose position is different between the geldanamycin-bound and free conformations. These are HSP90
residues 100–134 (numbers in parentheses), corresponding to residues 135–174 in GRP94. Yellow highlight, position 125; gray highlights, Asp128
and Gly132, residues mutated in the RadR mutant; green highlights, Ile115, Leu124, and Val126, residues contributing to the hydrophobic pocket.
Other residues from the hydrophobic pocket are Leu80, Ile84, Leu240, Ile243, Val247, Ile254, Ile258, Pro259, and Val260. Amino acids are colored blue for
E or D; red for K, R, or H; purple for N or Q; green for F or Y; brown for C; black for A, G, P, S, and T; and yellow for I, L, M, and V. B, model of
the hydrophobic pocket. A spacefill model showing the protein in the same view as in Fig. 2B, left panel. Peptides are shown in light green. Dark
green residues, I, L, and V; blue, F; purple, T; brown, P; yellow, C; light blue, H. Red arrow, Cys117; red arrowhead, His125. Red dashed line,
approximate location of the residues shown to cross-link to bis-ANS (28).
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here provides an important part of the answer by locating the
peptide-binding site. Together with our previous data (17), we
show that the peptide-binding site of the chaperone GRP94 is
located in a large groove in the N-terminal domain, opposite
the nucleotide/geldanamycin/radicicol-binding site. This pep-
tide-binding site was predicted by a computer docking algo-
rithm, and the following experimental observations are consist-
ent with the prediction: (a) residues 1–33 and 223–355 are
dispensable for retention of bound peptide, if not for binding;
(b) peptide binding is not hydrophobic in nature, consistent
with the rather hydrophilic nature of the site; (c) Cys117, lo-
cated in a hydrophobic pocket, is affected by peptide binding,
but can be modified covalently without inhibiting peptide bind-
ing; (d) alteration of the binding site for the inhibitor radicicol
does not prevent peptide binding; (e) the nature of residue 125
is critical for peptide binding and His-125 is protected from
modification with DEPC when peptide is bound; and (f) none of
the other 3 histidines in N1–355 seems to be involved.
Substitution of Asp for His125 is sufficient to abolish the
peptide binding activity of the protein. Although mutations
that reduce or abolish peptide binding can lie outside the bind-
ing pocket and act by affecting protein conformation, we show
physical association between His125 and peptide, because of the
protection from modification by the small molecule DEPC when
peptide is bound. Therefore, we propose that the curved  sheet
in the N-terminal domain is a peptide-binding site of this
chaperone, at least in vitro, and is not merely a regulatory site.
A more extensive survey of amino acids by mutagenesis and
other biochemical methods to map the extent of the binding site
is in progress.
If the computer-generated model is correct also in predicting
the mode of peptide association, then binding is along the axis
of the groove with contacts along the entire length of the
peptide, reminiscent of the interactions of peptides with the
groove of MHC class I proteins. The saddle-like geometry of the
proposed binding site would allow GRP94-binding peptides to
“slide” along the axis of the groove, accounting for the observa-
tion that VSV8 binds with similar kinetics to VSV19, a peptide
whose middle 8 amino acids are the VSV8 sequence. This
aspect of the binding site would also explain the ability of
GRP94 to bind peptides of different lengths, from 8-mers to
40-mers, with similar affinity (1, 15, 17).
While chaperones are generally thought to recognize hydro-
phobic peptides, as is true for HSP70s (31, 32), the features of
peptides recognized by GRP94 seem different. The GRP94
groove identified here is lined with basic side chains (lysines
and a histidine) and hydroxylic side chains (e.g. threonines),
with only few hydrophobic side chains. The two binder peptides
used in this work are also quite hydrophilic, their binding is
sensitive to pH (Ref. 17 and this report) and is dissociated with
high salt (17). Thus, binding of at least these peptides seems to
be driven by polar and electrostatic interactions, not hydropho-
bic. This observation is also consistent with the nature of the
rylodan was significantly higher than that of the free dye, indicating
covalent linkage. C, acrylodan conjugated N1–355 binds peptide to the
same extent as unconjugated N1–355. Free or acrylodan-conjugated
protein (3.6 M) was reacted with 800 M 125I-VSV8 under saturating
conditions and unbound peptide was removed using a spin column (17).
Free 125I-VSV8 was used to control for the efficiency of removal of the
unbound peptide. N1–355 and N1–355-acr, free and acrylodan-conju-
gated protein respectively; N1–355VSV8* and N1–355-acrVSV8*,
same proteins bound to 125I-VSV8; VSV8*, free 125I-VSV8 peptide. D,
fluorescence of acrylodan covalently bound to N1–355 is affected by the
addition of peptide. Fluorescence emission scans of acrylodan-conju-
gated N1–355 in the presence of either VSV8 (800 M final concentra-
tion) or equivalent volume of buffer were taken at excitation wave-
length 390 nm. VSV8 alone had no fluorescence in the measured
wavelength range.
FIG. 5. Peptide binding affects the environment of the hydro-
phobic pocket containing Cys117. A, peptide A binding affects the
emission of N1–355-bound ANS. N1–355 was first reacted with ANS
(N1–355-ANS) and then bound to saturating amount of peptide A
(N1–355-ANSpeptA). Emission maximum of N1–355-ANS is 478 nm,
indicating a highly hydrophobic environment. Addition of peptide A
partially quenches the fluorescence of N1–355-ANS, but not that of free
ANS. N1–355 itself does not fluoresce in the wavelength range shown.
B, acrylodan binds covalently to the Cys within the predicted hydro-
phobic pocket. N1–355 and N34–355 were reacted with acrylodan over-
night at 4 °C. A sample with identical amount of acrylodan without
protein served as a control. Half of each sample was then supplemented
with guanidine chloride to a final concentration of 6 M and another with
equivalent volume of buffer. The emission maximum of N1–355-bound
acrylodan under non-denaturing conditions was around 473 nm, indi-
cating highly hydrophobic environment. In 6 M guanidine chloride, the
emission maxima were around 522 nm for both N1–355-bound and free
acrylodan, whereas the fluorescence intensity of the protein-bound ac-
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His125 mutations that affect binding: replacing the imidazole
ring with a Tyr side chain still allowed partial binding, and
substituting with Asp completely inhibited binding. It will also
be of interest to determine whether the H125D mutant is still
capable to chaperone proteins.
The  strands that form the floor for the peptide-binding site
separate it from the radicicol-binding pocket. The  sheet in the
center of the domain appears to play a role in both activities of
the N-terminal domain. This is clearly demonstrated here for
strand F of this  sheet (Fig. 4A). It contains at least one
residue, Asp128, whose side chain is directed toward, and is
important for binding to radicicol, as predicted from the homol-
ogy with HSP90 (23) and shown directly in this work. The same
strand F also houses His125, whose central role in peptide
binding is demonstrated here. Yet, despite their proximity,
substitution of residues on the side of the strand that contacts
the inhibitor does not significantly affect the contacts on the
other side of the strand with bound peptide, and vice versa. We
show that a radicicol-refractive mutant is able to bind peptide
and that a mutant in peptide binding still responds normally to
radicicol. Peptide binding can be inhibited by binding of radi-
cicol, but the inhibitor has to occupy its binding site first (17).
This suggests that binding of radicicol transmits a unidirec-
tional change, either across the  sheet or more indirectly, so as
to alter the peptide-binding groove.
The crystal structure of HSP90 has been solved both in the
presence and absence of geldanamycin/radicicol/ATP, and the
differences in structure help define the conformational change
induced by occupation of the nucleotide site (22–23, 26, 33). The
two forms differ in three helices and a loop, about 35 residues
altogether, which mostly either enable or constrain the en-
trance to the nucleotide-binding pocket. The corresponding re-
gion in GRP94 is amino acids 135–174 (Fig. 4A). There is no
obvious difference in the  sheet that would explain the inhi-
bition of peptide binding by geldanamycin or radicicol. The
observed inhibition, therefore, could be due to subtle changes or
to more indirect transmission of conformational change from
the 135–174 region to the opposite side of the molecule.
The identification of the peptide-binding site of GRP94 has
direct relevance to all HSP90 proteins, because they have been
reported to bind peptides, but none of their binding sites has
yet been mapped. Scheibel et al. (34) showed that the N-termi-
nal 210 amino acids of yeast HSP90 form a monomeric domain
sufficient to bind peptides, in geldanamycin- and ATP-sensitive
manner, much like the minimal GRP94 construct described
here. Addition of the negatively charged domain to the N-
terminal domain increases peptide-binding affinity without af-
fecting specificity (35). Another similarity between yeast
HSP90 and murine GRP94 is the apparent non-equilibrium
nature of peptide binding (17, 35, and this report). Comparison
of residues contributing to the saddle-like binding site shows
that His125 is absent from all HSP90s, replaced by Thr in most
HSP90 sequences. Because the HSP90 1–210 domain binds
VSV8 less tightly than longer peptides (35), it is possible that
the HSP90 N-terminal site is not as efficient in peptide binding
as that of GRP94 or that its peptide specificity is different. An
unresolved question for all HSP90 family members is the loca-
tion of their client protein interaction site, and at least in the
case of the kinase Akt this interaction is thought to be medi-
ated by the middle domain of HSP90, rather than the N-
terminal domain (37).
It is instructive to compare peptide binding by GRP94 with
other peptide-binding sites. In HSP70 proteins, peptides also
bind on top of a  sheet delineated by loops from the  sandwich
domain (36, 38). The peptide makes contacts with three 
strands and is perpendicular to them, and the binding groove
has both hydrophobic and polar amino acids, but no charged
residues (36, 38). In comparison, the GRP94 peptide groove is
wider and is made up of mostly polar residues, and the peptide
makes contacts more or less along the axis of three strands
(strands G, F, and H). The interaction of GRP94 with peptide
has several features in common with MHC proteins. In both
MHC class I and class II the association constants are low and
the off-rates very slow. GRP94-peptide complexes are very sta-
ble, resistant even to SDS, like many MHC-peptide complexes
(39). When complexed with the Kb class I protein, the same
VSV8 peptide used in the current work lies at approximately a
45° across a three-strand  sheet, constrained between two 
helices (8), a topology that is similar to the one we suggest for
the GRP94 binding groove. Interestingly, just like strand F,
which provides important contact residues also on the other
face of the  sheet with the inhibitors geldanamycin or radici-
col, the same three  strands in MHC class I that interact with
peptide also provide important contacts on the other face of the
sheet with the 2m subunit of the protein (40). Depending on
the MHC allele (41), mutations in 2m can alter such contacts
and affect peptide loading on the other face of the  sheet (42).
MHC-peptide complexes are designed to leave one face of the
bound peptide solvent-accessible, available for subsequent con-
tacts with a T cell receptor. In HSP70 proteins, on the other
hand, the bound peptide is buried, locked in place by an -hel-
ical domain acting as a reversible latch, whose motion is con-
TABLE I
Protection of His125 from modification by peptide binding
Wild type N34–355 or the H125D mutant proteins were incubated with saturating concentration of peptide A (or buffer alone) and the complexes
purified by spin column gel filtration. Proteins or protein-peptide complexes were then modified with DEPC (or the ethanol solvent alone) and
adsorbed onto gold Ciphergen Protein chips. Masses of the treated proteins were determined by SELDI-TOF on a Ciphergen mass spectrometer
calibrated with a standard set of proteins and peptides. The values given are for the single ionized peaks in each sample. They are from one
experiment.
Protein and treatment Observed molecular mass Observed differencea Expected differenceb
Da
Wild type 37,742
Wild type  DEPC 38,031 289 288 (4)
Wild type  DEPC  HA 37,758 16 0
Wild type  peptide A DEPC 37,955 213 216 (3)
H125D 37,767
H125D  DEPC 37,978 211 216 (3)
H125D  DEPC  HA 37,737 30 0
H125D  peptide A DEPC 37,982 215 216 (3)
a The observed differences were calculated with respect to the unmodified protein (either wild type of H125D). The calculated molecular mass
of wild type N34–355 is 37,781 Da, and that of the H125D mutant is 22 Da smaller. The differences obtained in two additional experiments were
essentially identical.
b The expected differences were calculated based on modification of three or four His residues (indicated in parenthesis) and the addition of 72
Da to the mass of the protein by N-carbethoxy modification of each His.
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trolled by a nucleotide-induced conformational change (38).
Our present data are not sufficient to decide whether GRP94-
peptide complexes resemble one or the other models. It is
possible that the second, acidic domain of GRP94 provides a
locking mechanism for peptide, because it is needed for at least
one activity of the N-terminal domain (25), and because it is
involved a conformational change induced by binding of inhib-
itor to the N-terminal domain (17). The recently published
structure of the N-terminal residues 48–316 of GRP94 (43)
(residues 69–337 in the nomenclature used in that report)
shows no obvious part acting to constrain the bound peptide
from above. On the other hand, the acidic domain is unordered
in the crystal structure and therefore can potentially regulate
access to the peptide-binding pocket, in analogy to the long
helix in HSP70 proteins (38). It is important to determine what
structural feature “locks” the bound peptide, because on the
one hand, peptides have been reported to have extremely high
avidity to GRP94 (e.g. Refs. 1, 17, and 44), yet antigen presen-
tation in vivo requires transfer of the GRP94-bound peptide to
MHC proteins.
The peptide-binding site identified in this work may account
for the T cell stimulatory activity of GRP94. Together with the
data showing that the N-terminal GRP94 fragment can bind to
antigen-presenting cells and activate T cells (45), our data
indicate that immunologically relevant peptides bind at this
FIG. 6. Peptide binding requires His residues. A, peptide binding
is pH-dependent. Binding of N1–355 to the peptide VSV8 was assessed
at various pH values using the solution binding assay described previ-
ously (17). At pH 7.2, either Hepes or Pipes were used with equal
results, and the average set to 100%. Hepes was used at pH 8.2, and
Pipes was used at pH 6.2, with the average binding values normalized
to that obtained at the standard pH of 7.2. B, peptide binding is
sensitive to imidazole. Binding of N34–355 to peptide A was measured
using the 96-well plate assay (“Experimental Procedures”). Imidazole
was added to the indicated final concentrations, and the binding at each
concentration normalized to that without imidazole. Peptide binding in
the presence of radicicol is shown as a measure of the nonspecific
binding. Triangles, binding in the absence on the inhibitor; squares,
binding in the presence of radicicol. C, binding activity is abolished by
DEPC modification. The His6 tag of recombinant N355 was cleaved
with factor Xa according to the manufacturer’s instructions (Novagen)
and the protein re-purified over a Ni-NTA column. The protein was
treated with DEPC, as described under “Experimental Procedures,” to
modify histidines selectively. A portion of the modified protein was
treated with 0.4 M hydroxylamine (HA), to reverse the DEPC effect.
Modification with ethanol was used as a solvent control. Radicicol
treatment was used to measure specific peptide binding. The untreated
and modified proteins were allowed to bind to peptide A-coated plates
(0.7 g of protein per well) and binding was quantified by indirect
reaction with 9G10 monoclonal antibody (Affinity Bioreagents) followed
by horseradish peroxidase-goat anti-rat (Jackson Laboratories). Tripli-
cate data points are from a representative experiment. DEPC decreased
binding to the background level, whereas HA completely reversed the
DEPC effect. Removal of the His6 tag had no effect on either efficiency
or specificity of binding. R, radicicol; Et, ethanol; DEP, treatment with
DEPC; HA, treatment with DEPC followed by hydroxylamine.
FIG. 7. Site-directed mutagenesis demonstrates the impor-
tance of histidine 125 for peptide binding. A, alteration of His125
affects N34–355 binding to peptide A, Wild type N34–355, H125Y, or
H125D proteins were purified by metal chelate chromatography and
their ability to bind peptide was tested in the plate assay (see “Exper-
imental Procedures”). Inhibition by radicicol (300 M) served as a spec-
ificity control (Rad). The binding was measured at two protein input
levels (0.7 or 2 g) based on the level of saturation binding for the WT
protein. The data shown are averages and standard error of triplicate
points in two experiments. Black bars, 0.7 g of protein; gray bars, 2 g
of protein. B, fractional occupancy curves of wild type and H125Y. The
amounts of peptide-bound protein, calculated as a fraction of the satu-
ration binding level for each protein, is shown as a function of the input
of protein. Filled squares, values from three independent dose-binding
experiments for the wild type protein. Empty squares, values from three
independent experiments for H125Y. C, the H125D mutant shows the
expected structural change upon radicicol binding. H125D and H125Y
were compared with WT protein using blue native gel electrophoresis.
Each protein (10 g) was treated with either 300 M radicicol or with
Me2SO and then loaded on each of two adjacent gel lanes. After elec-
trophoresis, the gel was stained with Coomassie Blue. Wild type and
H125D proteins migrated predominantly as monomers and the charac-
teristic radicicol-induced mobility shift was observed for both. Although
H125Y protein also migrated as a monomer, it was present in two
different conformations. Approximately half of H125Y showed in-
creased mobility even in the absence of radicicol, whereas the other half
showed both expected mobility and radicicol-induced conformational
change. Black arrow, unbound protein; white arrow, radicicol-bound
protein.
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site and that the N1–355 fragment of GRP94 may suffice to
account for peptide-specific activation of T cells. Because this
site can be regulated by ligands that bind to the nucleotide site
and to the hydrophobic pocket, binding of peptide to this site
can be regulated by intracellular co-factors that are yet to be
discovered.
Acknowledgments—We thank Steven Dimirsky for purification of
recombinant proteins and all members of the lab for helpful discussions.
REFERENCES
1. Blachere, N. E., Li, Z., Chandawarkar, R. Y., Suto, R., Jaikaria, N. S., Basu, S.,
Udono, H., and Srivastava, P. K. (1997) J. Exp. Med. 186, 1315–1322
2. Singh-Jasuja, H., Scherer, H. U., Hilf, N., Arnold-Schild, D., Rammensee,
H. G., Toes, R. E., and Schild, H. (2000) Eur. J. Immunol. 30, 2211–2215
3. Tamura, Y., Peng, P., Liu, K., Daou, M., and Srivastava, P. K. (1997) Science
278, 117–120
4. Suto, R., and Srivastava, P. K. (1995) Science 269, 1585–1588
5. Binder, R. J., Han, D. K., and Srivastava, P. K. (2000) Nat. Immunol. 1,
151–155
6. Argon, Y., and Simen, B. B. (1999) Semin. Cell Dev. Biol. 10, 495–505
7. Imarai, M., Goyarts, E. C., van Bleek, G. M., and Nathenson, S. G. (1995) Cell.
Immunol. 160, 33–42
8. Zhang, W., Young, A. C., Imarai, M., Nathenson, S. G., and Sacchettini, J. C.
(1992) Proc. Natl. Acad. Sci. U. S. A. 89, 8403–8407
9. Nieland, T. J., Tan, M. C., Monne-van Muijen, M., Koning, F., Kruisbeek,
A. M., and van Bleek, G. M. (1996) Proc. Natl. Acad. Sci. U. S. A. 93,
6135–6139
10. Wearsch, P. A., and Nicchitta, C. V. (1997) J. Biol. Chem. 272, 5152–5156
11. Wearsch, P. A., Voglino, L., and Nicchitta, C. V. (1998) Biochemistry 37,
5709–5719
12. Meng, S. D., Gao, T., Gao, G. F., and Tien, P. (2001) Lancet 357, 528–529
13. Breloer, M., Marti, T., Fleischer, B., and von Bonin, A. (1998) Eur. J. Immunol.
28, 1016–1021
14. Ishii, T., Udono, H., Yamano, T., Ohta, H., Uenaka, A., Ono, T., Hizuta, A.,
Tanaka, N., Srivastava, P. K., and Nakayama, E. (1999) J. Immunol. 162,
1303–1309
15. Spee, P., and Neefjes, J. (1997) Eur. J. Immunol. 27, 2441–2449
16. Baker-LePain, J. C., Reed, R. C., and Nicchitta, C. V. (2003) Curr. Opin.
Immunol. 15, 89–94
17. Vogen, S. M., Gidalevitz, T., Biswas, C., Simen, B. S., Stein, E., Gulmen, F.,
and Argon, Y. (2002) J. Biol. Chem. 277, 40742–40750
18. Schagger, H., Cramer, W. A., and von Jagow, G. (1994) Analyt. Biochem. 217,
220–230
19. Kalkum, M., Przybylski, M., and Glocker, M. O. (1998) Bioconjug. Chem. 9,
226–235
20. Rai, S. S., and Wolff, J. (1998) J. Biol. Chem. 273, 31131–31137
21. Robert, J., Menoret, A., Basu, S., Cohen, N., and Srivastava, P. R. (2001) Eur.
J. Immunol. 31, 186–195
22. Prodromou, C., Roe, S. M., O’Brien, R., Ladbury, J. E., Piper, P. W., and Pearl,
L. H. (1997) Cell 90, 65–75
23. Roe, S. M., Prodromou, C., O’Brien, R., Ladbury, J. E., Piper, P. W., and Pearl,
L. H. (1999) J. Med. Chem. 42, 260–266
24. Schneidman-Duhovny, D., Inbar, Y., Polak, V., Shatsky, M., Halperin, I.,
Benyamini, H., Barzilai, A., Dror, O., Haspel, N., Nussinov, R., and
Wolfson, H. J. (2003) Proteins 52, 107–112
25. Schulte, T. W., Akinaga, S., Murakata, T., Agatsuma, T., Sugimoto, S.,
Nakano, H., Lee, Y. S., Simen, B. B., Argon, Y., Felts, S., Toft, D. O.,
Neckers, L. M., and Sharma, S. V. (1999) Mol. Endocrinol. 13, 1435–1448
26. Stebbins, C. E., Russo, A. A., Schneider, C., Rosen, N., Hartl, F. U., and
Pavletich, N. P. (1997) Cell 89, 239–250
27. Prodromou, C., Siligardi, G., O’Brien, R., Woolfson, D. N., Regan, L.,
Panaretou, B., Ladbury, J. E., Piper, P. W., and Pearl, L. H. (1999) EMBO
J. 18, 754–762
28. Wassenberg, J. J., Reed, R. C., and Nicchitta, C. V. (2000) J. Biol. Chem. 275,
22806–22814
29. Slavik, J. (1982) Biochim. Biophys. Acta 694, 1–25
30. Prendergast, F. G., Meyer, M., Carlson, G. L., Iida, S., and Potter, J. D. (1983)
J. Biol. Chem. 258, 7541–7544
31. Blond-Elguindi, S., Cwirla, S. E., Dower, W. J., Lipshutz, R. J., Sprang, S. R.,
Sambrook, J. F., and Gething, M. J. (1993) Cell 75, 717–728
32. Gragerov, A., and Gottesman, M. E. (1994) J. Mol. Biol. 241, 133–135
33. Prodromou, C., Roe, S. M., Piper, P. W., and Pearl, L. H. (1997) Nat. Struct.
Biol. 4, 477–482
34. Scheibel, T., Weikl, T., and Buchner, J. (1998) Proc. Natl. Acad. Sci. U. S. A.
95, 1495–1499
35. Scheibel, T., Siegmund, H. I., Jaenicke, R., Ganz, P., Lilie, H., and Buchner, J.
(1999) Proc. Natl. Acad. Sci. U. S. A. 96, 1297–1302
36. Burkholder, W. F., Zhao, X., Zhu, X., Hendrickson, W. A., Gragerov, A., and
Gottesman, M. E. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 10632–10637
37. Fontana, J., Fulton, D., Chen, Y., Fairchild, T. A., McCabe, T. J., Fujita, N.,
Tsuruo, T., and Sessa, W. C. (2002) Circ. Res. 90, 866–873
38. Zhu, X., Zhao, X., Burkholder, W. F., Gragerov, A., Ogata, C. M., Gottesman,
M. E., and Hendrickson, W. A. (1996) Science 272, 1606–1614
39. Collins, E. J., and Frelinger, J. A. (1998) Immunol. Rev. 163, 151–160
40. Shields, M. J., Assefi, N., Hodgson, W., Kim, E. J., and Ribaudo, R. K. (1998)
J. Immunol. 160, 2297–2307
41. Smith, R. A., Myers, N. B., Robinson, M., Hansen, T. H., and Lee, D. R. (2002)
J. Immunol. 169, 3105–3111
42. Shields, M. J., Kubota, R., Hodgson, W., Jacobson, S., Biddison, W. E., and
Ribaudo, R. K. (1998) J. Biol. Chem. 273, 28010–28018
43. Soldano, K. L., Jivan, A., Nicchitta, C. V., and Gewirth, D. T. (2003) J. Biol.
Chem.
44. Liu, C., Ewing, N., and DeFilippo, M. (2004) Methods 32, 32–37
45. Baker-LePain, J. C., Sarzotti, M., Fields, T. A., Li, C. Y., and Nicchitta, C. V.
(2002) J. Exp. Med. 196, 1447–1459
The Peptide-binding Site of GRP9416552
